ACH · Accendra Health Inc/Va/
Market Cap
$93.05M
Shares
76.90M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.76B
+3.1%
FY2025
Net Income
-$1.1B
-203.5%
FY2025
Gross Margin
82.8%
-0.5pp
FY2024
Operating Margin
0.99%
+9.1pp
FY2025
Diluted EPS
-$14.31
-202.5%
FY2025
Operating Cash Flow
-$101.79M
-163%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.45B – $2.55B | $2.65B | $2.76BG | $2.68BG | $2.55BG | $9.96BG | $9.79B | $8.48B | $9.21B | $9.42B | $9.32B | $9.72B | $9.77B | $9.44B | $9.07B | $8.87B | $8.63B | $8.12B | $8.04B | $7.24B | |
| — | $1.46B | $1.47B | $1.4B | $1.34B | $8.13B | $8.27B | $7.2B | $8.08B | $8.35B | $8.15B | $8.54B | $8.56B | $8.27B | $7.95B | $7.94B | $7.77B | $7.32B | $7.22B | $6.5B | |
| — | $2.21B | — | $2.22B | $2.13B | $1.83B | $1.51B | $1.28B | $1.13B | $1.07B | $1.17B | $1.19B | $1.21B | $1.17B | $1.12B | $924.65M | $857.54M | $807.73M | $814.39M | $741.11M | |
| — | — | — | 82.8% | 83.26% | 18.35% | 15.46% | 15.1% | 12.25% | 11.37% | 12.58% | 12.21% | 12.43% | 12.39% | 12.31% | 10.43% | 9.94% | 9.94% | 10.13% | 10.23% | |
| — | — | — | $13M | $13M | $12M | $12.1M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1.04B | $1.07B | $1.08B | $1B | $1.55B | $1.08B | $1.04B | $1.02B | $952.87M | $1.02B | $970.42M | $993.78M | $984.1M | $863.66M | $682.6M | $610.66M | $564.17M | $592.34M | $544.89M | |
| — | $116.8M | $74M | $40M | $58M | $78.85M | $39.8M | $41.5M | $44M | $35.1M | $16.4M | $10M | $9.8M | $5.5M | $3.3M | $2.5M | $3.1M | $3M | $3M | — | |
| — | $256.08M | $214.52M | $181.28M | $210.37M | $228.67M | $90.62M | $93.34M | $116.68M | $101.93M | $59.44M | $55.39M | $65.98M | $63.41M | $50.59M | $39.6M | $34.14M | $29.15M | $25.27M | $21.96M | |
| — | — | — | — | — | — | — | — | — | $10.33M | $17.69M | $11.82M | $5.08M | $11.93M | $3.06M | $1.18M | $11.36M | — | — | — | |
| — | $29.35M | $27.46M | -$217.73M | $133.23M | $142.91M | $368.47M | $204.12M | $73.15M | -$352.35M | $89.25M | $199.6M | $200.36M | $159.54M | $198.08M | $196.75M | $203.52M | $195.94M | $201.28M | $180.73M | |
| — | — | 0.99% | -8.12% | 5.22% | 1.44% | 3.77% | 2.41% | 0.79% | -3.74% | 0.96% | 2.05% | 2.05% | 1.69% | 2.18% | 2.22% | 2.36% | 2.41% | 2.5% | 2.5% | |
| — | $285.43M | $241.98M | -$36.45M | $343.6M | $371.58M | $459.09M | $297.45M | $189.83M | -$250.42M | $148.69M | $254.99M | $266.34M | $222.94M | $248.67M | $236.36M | $237.65M | $225.08M | $226.54M | $202.68M | |
| — | $123.85M | $107.18M | $107.57M | $116.77M | $128.89M | $48.09M | $83.4M | $98.11M | $70.98M | $31.77M | $27.06M | $27.15M | $18.16M | $13.1M | $13.4M | $13.68M | $14.32M | $13.03M | $16M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $13.4M | $13.68M | $14.32M | — | — | |
| — | -$3.69M | -$3.94M | -$4.59M | -$1.2M | -$3.13M | -$3.2M | $407K | -$2.93M | -$3.77M | — | — | — | — | — | — | — | — | — | — | |
| — | -$115.48M | -$101.95M | -$329.89M | $15.27M | $10.89M | $276.75M | $109.91M | -$28.72M | -$427.09M | $57.48M | $172.54M | $173.21M | $126.48M | $184.99M | $183.36M | $189.83M | $181.61M | $188.25M | $164.73M | |
| — | -$4.89M | $729K | $20.85M | $6.36M | -$11.5M | $55.17M | $21.83M | -$6.14M | -$32.43M | -$15.32M | $63.76M | $69.8M | $59.98M | $74.1M | $74.35M | $74.64M | $71.03M | $71.39M | $63.47M | |
| — | -$302.14M | -$1.1B | -$362.69M | -$41.3M | $22.39M | $221.59M | $29.87M | -$62.37M | -$437.01M | $72.79M | $108.79M | $103.41M | $66.5M | $110.88M | $109M | $115.2M | $110.58M | $104.66M | $93.33M | |
| — | — | -39.85% | -13.53% | -1.62% | 0.22% | 2.26% | 0.35% | -0.68% | -4.64% | 0.78% | 1.12% | 1.06% | 0.7% | 1.22% | 1.23% | 1.34% | 1.36% | 1.3% | 1.29% | |
| — | — | — | — | — | — | — | — | — | -$437.01M | $71.73M | $107.64M | $102.48M | $65.91M | $110.14M | $108.25M | $114.14M | $109.41M | $115.58M | — | |
| — | -$272.97M | -$1.05B | -$380.21M | -$37.26M | $27.13M | $219.51M | $44.07M | -$69.47M | -$457.54M | $115.19M | $93.13M | $75.59M | $32.93M | — | $116.09M | $112.82M | $118.5M | $103.72M | $88.51M | |
| USD/shares | — | -$3.93 | -$14.31 | -$4.73 | -$0.54 | $0.30 | $3.05 | $0.47 | -$1.03 | — | — | $1.76 | $1.65 | $1.06 | $1.76 | $1.72 | $1.82 | $1.76 | $1.68 | $1.51 |
| USD/shares | — | -$3.93 | -$14.31G | -$4.73G | -$0.53G | $0.29G | $2.94 | $0.47 | -$1.03 | — | — | $1.76 | $1.65 | $1.06 | $1.76 | $1.72 | $1.81 | $1.75 | $1.67 | $1.50 |
| shares | — | — | 76.9M | 76.74M | 75.79M | 74.5M | 72.74M | 63.37M | 60.57M | 60.01M | 60M | 61.09M | 62.12M | 62.22M | 62.63M | 62.77M | 62.76M | 62.32M | 61.72M | — |
| shares | — | — | 76.9M | 76.74M | 77.37M | 76.22M | 75.49M | 63.51M | 60.57M | 60.01M | 60M | 61.09M | 62.12M | 62.23M | 62.66M | 62.84M | 62.92M | 62.56M | 62.08M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $166.14M in buybacks, $591.61M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Distribution median 0.26×
EV/EBIT
—
Medical Distribution median 20.51×
P/E (TTM)
—
Medical Distribution median 23.96×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Products Healthcare Services | $8,020,771,000 | $7,781,395,000 | $7,898,397,000 | $8,825,646,000 | $7,662,429,000 | — | — |
| Patient Direct | $2,680,112,000 | $2,552,572,000 | $2,057,078,000 | $959,669,000 | $817,748,000 | — | — |
| Global Products | — | — | — | — | — | $1,433,977,000 | $1,111,322,000 |
| Global Solutions | — | — | — | — | — | $8,243,867,000 | $8,767,549,000 |
By Geography (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| United States | $10,457,942,000 | $10,058,675,000 | $9,526,037,000 | $9,250,331,000 | $8,130,411,000 | $8,871,599,000 | $9,261,149,000 |
| Non Us | $242,941,000 | $275,292,000 | $429,438,000 | $534,984,000 | $349,766,000 | $339,340,000 | $157,043,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Diabetes Product | $783,370,000 | $777,483,000 | $723,318,000 |
| Sleep Therapy Product | $740,052,000 | $702,950,000 | $669,784,000 |
| Home Respiratory Therapy Product | $433,050,000 | $435,954,000 | $457,675,000 |
| Product And Service Other | $288,192,000 | $268,274,000 | $254,971,000 |
| Ostomy | $212,838,000 | $195,923,000 | $177,890,000 |
| Wound Care | $188,508,000 | $192,407,000 | $170,949,000 |
| Urology | $116,022,000 | $107,121,000 | $97,985,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Patient Direct | $260,155,000 | $246,863,000 | $193,748,000 | $57,966,000 | $67,662,000 | — | — |
| Products Healthcare Services | $53,012,000 | $57,809,000 | $175,309,000 | $384,390,000 | $215,698,000 | — | — |
| Global Products | — | — | — | $371,929,000 | $259,929,000 | $65,054,000 | $75,688,000 |
| Global Solutions | — | — | — | $66,634,000 | $30,946,000 | $83,592,000 | $108,761,000 |
Operating Margin by Segment (%)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|
| Products Healthcare Services | 0.7% | 0.7% | 2.2% | 4.4% | 2.8% | — | — |
| Patient Direct | 9.7% | 9.7% | 9.4% | 6% | 8.3% | — | — |
| Global Products | — | — | — | — | — | 4.5% | 6.8% |
| Global Solutions | — | — | — | — | — | 1% | 1.2% |
Key facts
CIK
75252
CUSIP
690732102
13F (30d)
124 filings
119 filers
Visit website
Investor relations